Oxaliplatin and Docetaxel as First-line Therapy for Advanced Non-small Cell Lung Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00145418|
Recruitment Status : Terminated (low enrollment)
First Posted : September 5, 2005
Results First Posted : January 31, 2013
Last Update Posted : June 30, 2014
Oncology Specialists, S.C.
Information provided by (Responsible Party):
Dr. Sigrun Hallmeyer, Oncology Specialists, S.C.
|Study Design||Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment|
Carcinoma, Non-Small-Cell Lung
Drug: Oxaliplatin + Docetaxel
|Recruitment Details||patients recruited from clinical practice.|
|Pre-assignment Details||patients were screened to see if they met eligibility criteria. If criteria met, enrolled into study. Otherwise listed as screen failures.|
Due to lack of recruitment, the study was closed early and conclusions should not necessarily be drawn from the data presented for duration of response